LeonaBio, Inc. (LONA) - Total Liabilities
Based on the latest financial reports, LeonaBio, Inc. (LONA) has total liabilities worth $22.29 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore LONA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
LeonaBio, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of LeonaBio, Inc..
LeonaBio, Inc. Competitors by Total Liabilities
The table below lists competitors of LeonaBio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atinum Investment Co. Ltd
KQ:021080
|
Korea | ₩16.58 Billion |
|
Gamma Nu Inc
KQ:192410
|
Korea | ₩61.48 Billion |
|
Dawonsys Co.Ltd
KQ:068240
|
Korea | ₩1.13 Trillion |
|
Anam Electroni
KO:008700
|
Korea | ₩111.38 Billion |
|
Nature Holdings Co. Ltd.
KQ:298540
|
Korea | ₩268.76 Billion |
|
Aminologics Co.Ltd
KQ:074430
|
Korea | ₩30.52 Billion |
|
Alterity Therapeutics Limited
F:PBN
|
Germany | €2.65 Million |
|
Futebol Clube do Porto - Futebol S.A.D.
LS:FCP
|
Portugal | €517.23 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down LeonaBio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See LeonaBio, Inc. (LONA) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LeonaBio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LeonaBio, Inc. (2018–2025)
The table below shows the annual total liabilities of LeonaBio, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.36 Million | +361.77% |
| 2024-12-31 | $13.94 Million | -53.63% |
| 2023-12-31 | $30.06 Million | +30.59% |
| 2022-12-31 | $23.02 Million | +110.69% |
| 2021-12-31 | $10.92 Million | +106.85% |
| 2020-12-31 | $5.28 Million | -75.90% |
| 2019-12-31 | $21.91 Million | +10.55% |
| 2018-12-31 | $19.82 Million | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more